Our Science

Obexelimab

Obexelimab, an investigational drug, is a bifunctional monoclonal antibody engineered to mimic the natural antigen-antibody complex for the inhibition of B cells. By targeting CD19 and FcγRIIb, obexelimab is designed to inhibit a broad B cell population, including plasmablasts and a subpopulation of CD19 expressing plasma cells, each of which produces high amounts of autoantibodies which contribute to autoimmune disease pathogenesis. Co-engagement of CD19 and FcγRIIb by obexelimab has been shown to inhibit B cell activity, including antibody production, proliferation, cytokine secretion, B cell differentiation and antigen presentation to T cells.

• Rapid recovery of B cells upon withdrawal of therapy

  Preclinical and clinical data show that the return of B cells in circulation of patients receiving obexelimab was observed as soon as six weeks after discontinuation, compared with B cell recovery periods of six months or longer observed with anti-CD19 and anti-CD20 targeted depleting therapies.

• Enhanced disease management

  Obexelimab’s self-administered, subcutaneous injection regimen could help patients to manage their own disease.

• Continuous versus intermittent B cell inhibition

  Most B cell depleting agents are administered every six months by intravenous injection. Modest B cell recovery between doses can result in loss of efficacy. We believe obexelimab’s self-administered, subcutaneous injection regimen may ensure continuous suppression of B cell activity.